Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: Influence of thalidomide and lenalidomide during maintenance

Blood

Volumn 120, Issue 8, 2012, Pages 1597-1600

  Usmani, Saad Z ^a   Sexton, Rachel ^b   Hoering, Antje ^b   Heuck, Christoph J ^a   Nair, Bijay ^a   Waheed, Sarah ^a   Al Sayed, Yazan ^a   Chauhan, Nabeel ^a   Ahmad, Nisar ^a   Atrash, Shebli ^a   Petty, Nathan ^a   Van Rhee, Frits ^a   Crowley, John ^b   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGED; ARTICLE; AUTOTRANSPLANTATION; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); COLON CANCER; FEMALE; HUMAN; KIDNEY CANCER; LUNG CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SECOND CANCER; THYROID CANCER; TREATMENT INDICATION;

EID: 84865433840     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-421883     Document Type: Article

References (17)

1. Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med. 2004;351(18):1860-73.
2. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108(10):3289-3294.
3. Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111(4):1805-1810. (Pubitemid 351451485)
4. Palumbo A, Bringhen S, Rossi D, et al. A prospective, randomized phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;114:652.
5. Palumbo A, Hajek R, Delforge M, at el. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
6. Mateos MV, Oriol A, Martinez J, et al. A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:3.
7. Attal M, Lauwers VC, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791.
8. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.
9. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354(10):1021-30. (Pubitemid 43357806)
10. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138(2):176-85.
11. Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115(21):4168-4173.
12. Barlogie B, Tricot G, Haessler J, et al. Cytogenetically defined myelodysplasia after melphalanbased autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. Blood. 2008;111(1):94-100.
13. Papanikolaou X, Barlogie B, Usmani SZ. Therapy-related myeloid malignancies in myeloma. Mediterr J Hematol Infect Dis. 2011;3(1):e2011047.
14. Agresti A. A survey of exact inference for contingency tables. Stat Sci. 1992;7(1):131-153.
15. Cox DR. Regression tables and life tables. J R Stat Soc. 1972;34(2):187-202.
16. Gooley T, Leisenring W, Crowley J, Storer B. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
17. Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012;119(12):2731-2737.